PORT-77, an oral small molecule therapy being developed to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), by Gondolabio through its affiliate Portal Therapeutics, has been granted both orphan drug […] The post PORT-77 gets FDA orphan drug, fast track designations for EPP and XLP appeared first on Porphyria News.
